[go: up one dir, main page]

CR8680A - Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina - Google Patents

Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina

Info

Publication number
CR8680A
CR8680A CR8680A CR8680A CR8680A CR 8680 A CR8680 A CR 8680A CR 8680 A CR8680 A CR 8680A CR 8680 A CR8680 A CR 8680A CR 8680 A CR8680 A CR 8680A
Authority
CR
Costa Rica
Prior art keywords
receptor
piperazinylipiperidine
chemiokin
antagonists
derivatives
Prior art date
Application number
CR8680A
Other languages
English (en)
Inventor
Xue Chu-Biao
Cao Ganfeng
Huang Taishen
Chen Lihua
Zhang Ke
Wang Anlai
Meloni David
Glenn Joseph
Metcalf Brian
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CR8680A publication Critical patent/CR8680A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion se relaciona con compuestos de la formula ( I ), en donde los sustituyentes variabkles se definen en l apresente, que modulan la actividad o la union de los receptores de quimiocina, tal como CCRS. En algunas modalidades, los compuestos de la invencion son selectivos para CCRS. Los compuestos pueden usarse, por ejemplo, para tratar las enfermedades asociadas con la expresion o actividad del receptor de quimiocina, tales como enfermedades inflamatorias, enfermedades inmunes e infecciones vitales
CR8680A 2004-04-13 2006-10-09 Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina CR8680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56169704P 2004-04-13 2004-04-13
US57222104P 2004-05-18 2004-05-18

Publications (1)

Publication Number Publication Date
CR8680A true CR8680A (es) 2007-08-28

Family

ID=35150660

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8680A CR8680A (es) 2004-04-13 2006-10-09 Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina

Country Status (20)

Country Link
US (4) US7678798B2 (es)
EP (1) EP1734966B1 (es)
JP (2) JP4948395B2 (es)
KR (1) KR101235090B1 (es)
CN (1) CN103012374B (es)
AU (1) AU2005234596B8 (es)
BR (1) BRPI0509803A (es)
CA (1) CA2562235C (es)
CR (1) CR8680A (es)
EA (1) EA015517B1 (es)
EC (1) ECSP066925A (es)
ES (1) ES2431524T3 (es)
GE (1) GEP20094680B (es)
HU (1) HU229709B1 (es)
IL (1) IL178622A (es)
MX (1) MXPA06011722A (es)
NO (1) NO337788B1 (es)
NZ (1) NZ550370A (es)
RU (1) RU2369604C2 (es)
WO (1) WO2005101838A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834021B2 (en) 2002-11-27 2010-11-16 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
EA015517B1 (ru) * 2004-04-13 2011-08-30 Инсайт Корпорейшн Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2007143600A2 (en) 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
CN101293820B (zh) * 2007-04-27 2012-10-10 天津药明康德新药开发有限公司 5-三氟甲基-1-茚酮的合成方法
WO2009012259A1 (en) * 2007-07-16 2009-01-22 Incyte Corporation Pentafluorosulfanyl-substituted piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
KR101374409B1 (ko) * 2011-10-17 2014-03-18 성균관대학교산학협력단 비유전성 항생제 내성 저해제 및 이의 용도
MA41389A1 (fr) 2015-05-07 2018-06-29 Bristol Myers Squibb Co Utilisation de sulfones tricycliques en tant que modulateurs de rory
JP2019529522A (ja) 2016-10-10 2019-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子としての三環式スルホン類
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0672041T3 (da) * 1993-10-01 2002-02-25 Novartis Ag Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
GB9522372D0 (en) 1995-11-01 1996-01-03 Merck Sharp & Dohme Therapeutic agents
US5704960A (en) 1995-12-20 1998-01-06 Corning, Inc. Method of forming an optical fiber for reduced polarization effects in amplifiers
GB9603741D0 (en) 1996-02-22 1996-04-24 Lin Mei Treatment of water by electrolysis
HUP9904167A3 (en) 1996-07-01 2000-07-28 Schering Corp 1,4-disubstituted piperazine and piperidine derivatives, their use and pharmaceutical compositions containing the same
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
WO1998053817A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
WO1998054207A1 (en) 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
DE69818049T2 (de) 1997-06-23 2004-07-15 Tanabe Seiyaku Co., Ltd. Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
EP1659111A3 (en) 1999-05-04 2007-05-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
US7825121B2 (en) 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
CZ20013940A3 (cs) * 1999-05-04 2002-04-17 Schering Corporation Piperazinové deriváty uľitečné jako CCR5 antagonisté
ES2165274B1 (es) 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
AU2002255947B8 (en) * 2001-03-29 2005-11-17 Schering Corporation CCR5 antagonists useful for treating AIDS
ATE418542T1 (de) 2001-03-29 2009-01-15 Schering Corp Als ccr5-antagonisten verwendbare aryloxim- piperazine
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
CA2467555A1 (en) 2001-11-29 2003-08-14 Schering Corporation Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
AU2003207646C1 (en) 2002-01-22 2008-09-18 Vanderbilt University Treating stress response with chemokine receptor CCR5 modulators
CN101139343A (zh) * 2002-03-29 2008-03-12 先灵公司 作为ccr5拮抗药的哌啶和哌嗪化合物的合成
EP1534681A1 (en) 2002-06-27 2005-06-01 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0223223D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
WO2004056772A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
US7834021B2 (en) 2002-11-27 2010-11-16 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
AU2003293555A1 (en) 2002-12-17 2004-07-29 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PE20040769A1 (es) 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
JO2485B1 (en) 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
AU2003298369B2 (en) 2002-12-23 2009-08-27 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
CA2509406C (en) 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
US20040235855A1 (en) 2003-03-31 2004-11-25 Bharat Lagu Phospholipase C inhibitors for use in treating inflammatory disorders
ATE395062T1 (de) 2003-06-10 2008-05-15 Janssen Pharmaceutica Nv Kombination von opioiden und einem piperazin- derivat für die behandlung von schmerzen
JP2007505951A (ja) 2003-06-13 2007-03-15 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとしてのキノリルアミド誘導体類
EP1644366A1 (en) 2003-06-30 2006-04-12 Schering Corporation Mch antagonists for the treatment of obesity
CN101798299A (zh) 2003-11-03 2010-08-11 先灵公司 用作趋化因子受体抑制剂的双六氢吡啶衍生物
CA2550596C (en) 2003-12-18 2011-03-15 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
EA015517B1 (ru) 2004-04-13 2011-08-30 Инсайт Корпорейшн Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
EP1746997A4 (en) 2004-05-11 2010-12-29 Incyte Corp 3- (4-HETEROARYLCYCLOHEXYLAMINE) CYCLOPENTANCARBOXAMIDE AS MODULATORS OF CHEMOKIN RECEPTORS
AP2006003848A0 (en) 2004-06-28 2006-12-31 Incyte Corp 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
JP4116670B2 (ja) 2004-06-28 2008-07-09 インサイト コーポレイション ケモカイン受容体の調節剤としての３−アミノシクロペンタンカルボキサミド
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
MX2007008280A (es) 2005-01-06 2007-09-07 Schering Corp Sintesis de los antagonistas del receptor ccr5.
WO2006088920A1 (en) 2005-02-16 2006-08-24 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
KR20070107075A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ３ 길항제 활성을 갖는 신규의 헤테로사이클릭치환된 피리딘 또는 페닐 화합물
CN101142209A (zh) 2005-02-16 2008-03-12 先灵公司 具有cxcr3拮抗剂活性的吡嗪基取代的哌嗪-哌啶
JP2008530212A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有するピペラジン−ピペリジン
CA2598457A1 (en) 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
US7868006B2 (en) 2005-02-16 2011-01-11 Schering Corporation Heterocyclic substituted piperazines with CXCR3 antagonist activity
MX2007009949A (es) 2005-02-16 2007-09-26 Schering Corp Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3.
PE20061012A1 (es) 2005-02-23 2006-10-03 Schering Corp Derivados piperidinil piperazina como inhibidores de receptores quiomicina
MX2007010257A (es) 2005-02-23 2007-09-11 Schering Corp Derivados de piperidinil piperidina utiles como inhibidores de receptores de quimiocinas.
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
TW200745087A (en) 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
US20080108586A1 (en) 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection

Also Published As

Publication number Publication date
US20120295912A1 (en) 2012-11-22
IL178622A0 (en) 2007-02-11
JP4948395B2 (ja) 2012-06-06
HU229709B1 (en) 2014-05-28
ES2431524T3 (es) 2013-11-26
ECSP066925A (es) 2006-12-20
US8268826B2 (en) 2012-09-18
US20140155404A1 (en) 2014-06-05
IL178622A (en) 2012-10-31
CN103012374A (zh) 2013-04-03
WO2005101838A3 (en) 2006-03-02
JP2007532654A (ja) 2007-11-15
GEP20094680B (en) 2009-05-10
EP1734966B1 (en) 2013-07-31
KR20070008635A (ko) 2007-01-17
CA2562235A1 (en) 2005-10-27
NO337788B1 (no) 2016-06-20
RU2006139946A (ru) 2008-05-20
EP1734966A2 (en) 2006-12-27
WO2005101838A2 (en) 2005-10-27
WO2005101838A8 (en) 2006-05-11
AU2005234596B2 (en) 2011-06-02
HUP0600858A2 (en) 2008-10-28
EA015517B1 (ru) 2011-08-30
KR101235090B1 (ko) 2013-02-20
AU2005234596A8 (en) 2011-06-16
EA200601894A1 (ru) 2007-02-27
US9067921B2 (en) 2015-06-30
NZ550370A (en) 2009-09-25
RU2369604C2 (ru) 2009-10-10
CN103012374B (zh) 2015-05-20
CA2562235C (en) 2013-09-24
JP2012036210A (ja) 2012-02-23
EP1734966A4 (en) 2009-04-22
AU2005234596A1 (en) 2005-10-27
BRPI0509803A (pt) 2007-09-18
US7678798B2 (en) 2010-03-16
US20050261310A1 (en) 2005-11-24
AU2005234596B8 (en) 2011-06-16
US20090197887A1 (en) 2009-08-06
NO20065151L (no) 2007-01-04
MXPA06011722A (es) 2007-01-25
US8680104B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR8759A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores quimioquinas
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CL2009000245A1 (es) Compuestos derivados de heterociclil piridinilo, con actividad moduladora del receptor 5-ht6; composicion farmaceutica que los comprende y su uso para tratar la esquizofrenia, ansiedad, migrana, depresion, entre otros.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
GT201000146A (es) Derivados de alcanos azabicíclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotínicos de acetilcolina
CR8775A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
CR8680A (es) Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina
CL2012001352A1 (es) Compuestos heterocíclicos derivados de amina, moduladores del receptor s1p; composición farmacéutica que los comprende; uso para tratar enfermedades oculares, vasculares sistémicas inflamatorias, autoinmunitarias e inmunosupresión, cicatrización y dolor entre otras.
PA8796001A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
EA200800835A1 (ru) Циклопропиламины в качестве модуляторов рецептора гистамина н
AR047759A1 (es) Derivados de fenil - piperazina como moduladores de receptores muscarnicos